CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $17.39M, lower than 95% of all stocks globally
- PositionPrice-to-book is 21.98×, higher than 95% of its Medical Devices peers (median 2.69×)
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.81BILS602.99M · vs all stocks (USD)
Trailing P/E
66.10xvs Medical Devices peers
Revenue (TTM)
52.23MUSD17.39M · vs all stocks (USD)
Profit Margin
15.55%vs Medical Devices peers
Beta
0.0980xvs all stocks
52-Week Change
73.67%vs all stocks
Market Capitalization
1.81BILS602.99M · vs all stocks (USD)
Enterprise Value
1.81BILS602.79M · vs all stocks (USD)
Trailing P/E
66.10xvs Medical Devices peers
Forward P/E
91.73xvs Medical Devices peers
PEG Ratio
0.6610xvs Medical Devices peers
Price to Sales (TTM)
29.72xvs Medical Devices peers
Price to Book (MRQ)
21.98xvs Medical Devices peers
Enterprise to Revenue
27.46xvs Medical Devices peers
Enterprise to EBITDA
196.47xvs Medical Devices peers
Gross Margin
75.17%vs Medical Devices peers
Profit Margin
15.55%vs Medical Devices peers
Operating Margin
13.98%vs Medical Devices peers
Return on Assets (TTM)
4.05%vs Medical Devices peers
Return on Equity (TTM)
12.82%vs Medical Devices peers
Revenue (TTM)
52.23MUSD17.39M · vs all stocks (USD)
Revenue per Share (TTM)
1.61USDUpdated Aug 21, 2026Quarterly Revenue Growth
35.40%vs Medical Devices peers
Gross Profit (TTM)
39.39MUSD13.12M · vs all stocks (USD)
EBITDA (TTM)
12.57MUSD4.19M · vs all stocks (USD)
Net Income (TTM)
7.63MUSD2.54M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
33.70%vs Medical Devices peers
Operating Cash Flow (TTM)
18.02MUSD6.00M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
7.63MUSD2.54M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00ILSUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
52.23MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
12.84MUSDFY2025 · Dec 31, 2025Gross Profit
39.39MUSDFY2025 · Dec 31, 2025Operating Income
4.32MUSDvs all stocks (USD)
Pre-tax Income
7.71MUSDFY2025 · Dec 31, 2025Income Tax Expense
77.00KUSDFY2025 · Dec 31, 2025Net Income
7.63MUSDFY2025 · Dec 31, 2025EBIT
9.92MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
11.46MUSDFY2025 · Dec 31, 2025Research & Development
9.60MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
25.46MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.60MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.21MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.2000USDFY2025 · Dec 31, 2025EPS (Diluted)
0.1800USDFY2025 · Dec 31, 2025Basic Shares Outstanding
38.16MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
38.16MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
7.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
13.93MUSDFY2025 · Dec 31, 2025Free Cash Flow
12.18MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
67.70MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
7.63MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.54MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
77.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
1.20MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-3.39MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
607.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-477.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
6.74MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.75MUSDFY2025 · Dec 31, 2025Purchase of Investments
-15.77MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Other Investing Activity
20.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-17.49MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-832.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.38MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.21MUSDFY2025 · Dec 31, 2025Shares Outstanding
40.03MSharesUpdated Aug 21, 2026Float Shares
23.20MSharesUpdated Aug 21, 2026% Held by Insiders
9.52%vs all stocks
% Held by Institutions
10.72%vs all stocks
Total Cash per Share (MRQ)
1.60USDUpdated Aug 21, 2026Total Debt (MRQ)
6.71MUSD2.23M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0901xvs Medical Devices peers
Current Ratio (MRQ)
3.59xvs Medical Devices peers
Book Value per Share (MRQ)
2.04USDUpdated Aug 21, 2026Total Assets
112.92MUSDvs all stocks (USD)
Total Current Assets
84.89MUSDFY2025 · Dec 31, 2025Total Liabilities
39.70MUSDFY2025 · Dec 31, 2025Total Non-current Assets
28.03MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
17.53MUSDFY2025 · Dec 31, 2025Total Current Liabilities
22.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
67.70MUSDFY2025 · Dec 31, 2025Other Short-term Investments
1.43MUSDFY2025 · Dec 31, 2025Accounts Receivable
4.11MUSDFY2025 · Dec 31, 2025Inventory
7.13MUSDFY2025 · Dec 31, 2025Accounts Payable
2.43MUSDFY2025 · Dec 31, 2025Short-term Debt
1.07MUSDFY2025 · Dec 31, 2025Deferred Revenue
12.23MUSDFY2025 · Dec 31, 2025Long-term Debt
5.74MUSDFY2025 · Dec 31, 2025Common Stock (Book)
430.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-90.75MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
73.22MUSDvs all stocks (USD)
52-Week Low
2.39KILAUpdated Aug 21, 202652-Week High
5.17KILAUpdated Aug 21, 202652-Week Change
73.67%vs all stocks
Beta
0.0980xvs all stocks
50-Day MA
4.57KILAUpdated Aug 21, 2026200-Day MA
3.99KILAUpdated Aug 21, 2026Avg 10-Day Volume
122.01KSharesUpdated Aug 21, 2026Avg 30-Day Volume
84.69KSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.6800USDUpdated Aug 21, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Cash covers reported profit and gross profit is up, with margins high and growth slowing.
Reads
Cash-Backed Growth Configuration
Revenue has grown steadily, and the cash arriving matches reported profit.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 21.98×, higher than 95% of its Medical Devices peers (median 2.69×)Significant
Price-to-book: 21.98Industry median: 2.69Industry P95: 16.17Peers compared: 102
Financial Health
Altman Z-Score 9.41: safe zoneNotable
Altman Z-Score: 9.41
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $17.39M, lower than 95% of all stocks globallySignificant
Revenue (USD): 17,391,447.25Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Nuvectis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Bohui Innovation Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Seers Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cytek Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Xiao Feng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Achieve Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Starry Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
FDC Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Moshi Moshi Retail Corp PLC
5 interpretationsCash-Backed Growth ConfigurationFCF Ratios ElevatedCash-Flow Ratios ElevatedHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-DecelerationIndustry-Benchmarked ROA and Margin Elevated
The Trade Desk, Inc.
5 interpretationsCash-Backed Growth ConfigurationFCF Ratios ElevatedCash-Flow Ratios ElevatedHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-DecelerationIndustry-Benchmarked ROA and Margin Elevated
One Career Inc.
5 interpretationsCash-Backed Growth ConfigurationFCF Ratios ElevatedCash-Flow Ratios ElevatedHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-DecelerationIndustry-Benchmarked ROA and Margin Elevated